The UCLA AIDS Institute, the UCLA CFAR and the Jonsson Comprehensive Cancer Center are accepting applications for seed grants to fund multidisciplinary collaborative research between cancer and AIDS investigators on topics relevant to cancers that occur frequently in HIV-infected patients, including AIDS defining and non-AIDS defining malignancies. This includes research that will lead to the development of novel diagnostic, preventive and therapeutic strategies for both AIDS-defining and non-AIDS-defining malignancies, as well as research on the molecular/cellular mechanism, pathogenesis or epidemiology of cancer in persons living with HIV infection. Proposals from junior investigators (professorial or research series titles) are encouraged. Funds are being made available in conjunction with a supplement to the Cancer Center grant for sites having connections with the AIDS Malignancy Consortium (AMC), and from NCI-funded supplements to the UCLA CFAR and Cancer Center. Projects showing connection with the AMC, as well as those from junior investigators will be given preferential priority in funding. Note: Projects proposing to study only virologic aspects of cancer-associated viruses (i.e. KSHV, EBV, etc.) will not be supported by this mechanism.

**Funding level: Up to $50,000 for 1 year**

Proposals will be due by 4pm Monday October 1, 2012.

The project period will be one year, with the earliest start date of Nov 1, 2012.

**Investigator Eligibility**

Applicants must have a full-time UCLA faculty appointment (Acting Professor series, Adjunct Professor series, Clinical Professor series, Professor in Residence series, or Professor series) or be an eligible non-professorial junior investigator (investigators in the professional research series).

**Funding Criteria**

- All pilot projects funded must have evidence of approval or exemption from IRB(s), documentation of human subjects training for all key personnel, NIH clearance (if applicable), evidence of OHRP required project assurance, and any other required approval from the appropriate oversight or regulatory offices.
- Although IRB approval is not required prior to application, release of funding will be contingent on receipt of IRB approval or exemption for the proposed project.
- This award is for pilot projects only and does not support travel and equipment.
- Grants will be reviewed by a peer-review committee.
- Progress reports and end of project reports will be required.

Core facilities are available, on a recharge basis, in these areas: virology, cytometry, mouse/human chimera, gene and cellular therapy, biostatistics, mucosal immunology, clinical research facilitation and consultation via the UCLA CFAR.

**Instructions for formal proposals**

Applications must be submitted using standard PHS 398 format; applications must adhere to format and instructions as given in the PHS 398 Instruction Files. (http://grants.nih.gov/grants/funding/phs398/phs398.html)

Specifically, the following forms must be submitted:

- **Form Page 1**: Face Page  
  *(As this is an internal grant application, sections 12 and 13 are not required)*

- **Form Page 2**: Description, Performance Sites, Key Personnel, Other Significant Contributors, and Human Embryonic Stem Cells  

  *Note: Unlike NIH grants, provide the abstract in lay language.*

Some grants are funded by private foundations or individuals who have an interest in supporting innovative research projects. In addition, we will maintain a file of good applications that are not funded in the event that we identify a source of funding matching the research in the future.

The format of the lay abstract should follow these headings:

- Approach
- Significance and Innovation
AIDS Related Malignancies Research

- Why this proposal would not be funded by conventional funding sources, such as NIH.

- Form Page 4: Detailed Budget for Initial Budget Period  
  http://grants.nih.gov/grants/funding/phs398/fp4.doc

  *Note: A budget justification is required only if there are unusual expenses involved.

- Biographical Sketch Format Page
  http://grants.nih.gov/grants/funding/phs398/biosketch.doc

- Resources page
  http://grants1.nih.gov/grants/funding/phs398/resources.doc

- Research Plan
  The continuation page template (http://grants.nih.gov/grants/funding/phs398/continuation.doc) is to be used for the Research Plan, which must follow the format in Section 5.5 of the 398 Instructions, unless otherwise indicated:
  - 5.5.1. Introduction (Resubmission or Revision Applications only) – One page limit
  - 5.5.2 and 5.5.3 Specific Aims and Research Strategy – The page limit for both sections combined is 3 pages total.
    For the Research Strategy, clearly state the significance of the studies with sufficient methodology and statistical analysis to allow evaluation of feasibility.
  - 5.5.4 Inclusion Enrollment Report (Renewal or Revision Applications only)
  - 5.5.5 Bibliography and References Cited/Progress Report Publication List
  - 5.5.6 Protection of Human Subjects
  - 5.5.7 Inclusion of Women and Minorities
  - 5.5.8 Targeted/Planned Enrollment Table
  - 5.5.9 Inclusion of Children
  - 5.5.10 Vertebrate Animals
  - 5.5.11 Select Agent Research
  - 5.5.12 Multiple Project Director/Principal Investigator (PD/PI) Leadership Plan
  - 5.5.13 Consortium/Contractual Arrangements
  - 5.5.14 Letters of Support (e.g., Consultants)
  - 5.5.15 Resource Sharing Plan(s)

- In order to not burden the Biostatistics Core for preparation of seed grant applications, in-depth biostatistical analysis will be required only for those seed grants that are deemed likely to be funded. Following review, for those seed grant applications deemed appropriate for further biostatistics support, that support should be limited to no more than five hours.

- A one-page cover letter should be included, indicating the grant program to which the application is directed.

- All applicants are strongly encouraged to consult with the appropriate AIDS Institute Associate Director prior to submitting an application.
  - Basic and Translational Research – Jerome Zack, Ph.D. (jzack@ucla.edu)
  - Clinical Therapeutics and Biomedical Prevention – Ronald Mitsuyasu, M.D. (rmitsuya@mednet.ucla.edu)
  - International Health Services and Policy – Thomas Coates, Ph.D. (tcoates@mednet.ucla.edu)
  - Prevention and Clinical Research – Gail E. Wyatt, Ph.D. (gwyatt@mednet.ucla.edu)

An electronic copy of the application (pdf format preferred) must be sent to the UCLA AIDS Institute (aidsinst@ucla.edu) no later than 4:00 pm on October 1, 2012.

Emails will be sent out the following day confirming receipt.

Questions can be directed to Jina Lee at 310-794-7209 or aidsinst@ucla.edu.